Halozyme Therapeutics (HALO) 15.70 $HALO Halozy
Post# of 64119
Posted On: 03/04/2015 6:22:20 PM
Halozyme Therapeutics (HALO) 15.70 $HALO
Halozyme Q4 Loss Narrower-than-Expected, Revenues Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 03, 9:33AM CST
Halozyme (HALO) reports narrower year over year loss in its fourth quarter; Gives 2015 view.
JNJ: 101.65 (-0.69), HALO: 15.70 (+0.47), CBM: 33.97 (+0.02), BAX: 69.25 (-0.17)
Halozyme Therapeutics ups revenues 143% in Q4
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 9:06AM CST
HALO: 15.70 (+0.47)
Halozyme Therapeutics' (HALO) CEO Helen Torley on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Mar 02, 7:00PM CST
HALO: 15.70 (+0.47)
Halozyme Therapeutics reports 4Q loss
Automated Insights - Mon Mar 02, 5:27PM CST
SAN DIEGO (AP) _ Halozyme Therapeutics Inc. (HALO) on Monday reported a loss of $5.3 million in its fourth quarter.
HALO: 15.70 (+0.47)
Halozyme Therapeutics beats by $0.03, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 3:20PM CST
HALO: 15.70 (+0.47)
Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results
PR Newswire - Mon Mar 02, 3:15PM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the fourth quarter and full year ended December 31, 2014. Financial highlights for the fourth quarter include revenues of $30.4 million and a net loss of $5.3 million, or $0.04 per share. This compares to revenues of $12.5 million and a net loss of $22.0 million, or $0.19 per share, for the fourth quarter of 2013. Financial highlights for the full year 2014 include revenues of $75.3 million and a net loss of $68.4 million, or $0.56 per share. This compares to revenues of $54.8 million and a net loss of $83.5 million, or $0.74 per share, in the prior year.
HALO: 15.70 (+0.47)
Notable earnings after Monday’s close
Seeking Alpha - at Seeking Alpha - Sun Mar 01, 4:35PM CST
MBI: 9.37 (+0.09), GWRE: 53.37 (-0.73), CODI: 16.58 (-0.13), MDR: 3.43 (+0.10), HTGC: 14.46 (-0.02), NBR: 12.84 (+0.23), NTRI: 18.73 (-0.61), XON: 48.11 (-0.04), STKL: 10.00 (+0.40), OPWR: 11.67 (+0.08), CZR: 10.36 (-0.22), PANW: 143.51 (-5.39), INN: 13.74 (+0.21), CMLS: 3.13 (-0.18), MTDR: 22.94 (+0.50), ARNA: 4.32 (+0.28), MCEP: 6.36 (+0.06), SLXP: 157.13 (+0.63), BALT: 1.63 (-0.04), MYL: 55.60 (+0.16), SN: 13.98 (+0.97), EPIQ: 17.55 (+0.13), CHUY: 23.22 (-0.76), DTSI: 33.34 (-0.38), PRAA: 48.29 (-1.45), HALO: 15.70 (+0.47), CIM: 3.16 (-0.02), CKEC: 30.74 (-0.13)
Next Week In Biotech: Pacira PDUFA, Geron And Dendreon Report
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 27, 8:00AM CST
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
BRLI: 36.51 (+1.31), CASM: 1.34 (+0.08), AMRN: 1.69 (+0.15), XON: 48.11 (-0.04), OSIR: 17.80 (+0.28), CPIX: 6.63 (+0.23), AMED: 29.43 (-0.53), CTIC: 2.46 (+0.04), INSY: 58.07 (+2.09), ECYT: 6.73 (+0.62), CMRX: 40.74 (+0.25), KYTH: 39.90 (+0.21), TRIB: 18.60 (+0.17), GALE: 1.95 (+0.10), ARNA: 4.32 (+0.28), XLRN: 41.01 (-0.16), ACRX: 9.11 (+0.18), ENDP: 85.65 (-0.23), DPLO: 30.78 (-0.19), SLXP: 157.13 (+0.63), PPHM: 1.47 (-0.01), MYL: 55.60 (+0.16), CBPO: 79.71 (+1.71), RGEN: 25.11 (+0.20), HALO: 15.70 (+0.47), ALIM: 5.21 (+0.03), ACHN: 11.63 (-0.51), GERN: 2.81 (-0.15), DARA: 0.85 (-0.09), SCMP: 14.82 (-0.15), ICPT: 266.49 (+19.13), CDXS: 3.90 (+0.12), PCRX: 95.39 (+1.45), PBYI: 206.96 (+0.95), FOLD: 8.41 (-0.07)
Next Week In Biotech: Arena And Vivus Report, Radiesse And Avedro Ad Comms
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 20, 8:00AM CST
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
LXRX: 1.05 (+0.07), AMRN: 1.69 (+0.15), HWAY: 22.28 (-0.01), HLS: 42.72 (-0.42), CYBX: 71.19 (+0.83), ESRX: 84.83 (+0.48), ECYT: 6.73 (+0.62), DXCM: 59.88 (+0.83), NSTG: 12.28 (+0.84), SRPT: 14.06 (+0.70), HZNP: 21.17 (+0.20), MDXG: 10.02 (-0.18), DEPO: 23.64 (+0.65), ANIK: 39.46 (unch), NKTR: 13.39 (+0.45), KERX: 13.26 (+0.22), ALIM: 5.21 (+0.03), EPZM: 24.01 (+0.64), AEGR: 28.02 (+0.56), MDRX: 12.32 (-0.03), ELGX: 16.04 (+0.11), NUVA: 45.01 (+0.75), HPTX: 29.73 (-0.05), GNMK: 12.58 (-0.20), MDVN: 121.01 (-0.37), HBIO: 5.61 (-0.17), ACAD: 38.14 (unch), ST: 56.03 (+0.25), RPTP: 10.30 (+0.69), FMI: 47.29 (-0.24), GMED: 24.03 (+0.07), JAZZ: 172.74 (-3.56), PTCT: 70.45 (+1.37), INFI: 16.17 (+0.21), ARNA: 4.32 (+0.28), EXEL: 3.05 (+0.05), NEO: 4.72 (+0.11), EXAS: 21.90 (+0.84), ALKS: 70.80 (-2.00), HTWR: 84.68 (-0.02), MNKD: 5.94 (-0.22), IPXL: 40.40 (+0.47), SQNM: 3.65 (-0.04), HALO: 15.70 (+0.47), ISIS: 70.16 (+1.50), CLVS: 77.40 (+1.85), BIO: 132.91 (-0.24), BIOS: 5.21 (-0.21), PCRX: 95.39 (+1.45)
Shares of HALO Up 53.1% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Feb 18, 9:09AM CST
SmarTrend identified an Uptrend for Halozyme Therapeutics (NASDAQ:HALO) on January 5th, 2015 at $9.95. In approximately 1 month, Halozyme Therapeutics has returned 53.07% as of today's recent price of $15.23.
HALO: 15.70 (+0.47)
Track What Biological Products Companies Are Up To: Special Research on Gilead, Halozyme, Heska, Idera, and Kite Pharma
PR Newswire - Tue Feb 17, 7:50AM CST
Editor Note: For more information about this release, please scroll to bottom.
HALO: 15.70 (+0.47), IDRA: 4.75 (+0.12), HSKA: 22.39 (+0.87), KITE: 63.19 (+1.72), GILD: 103.06 (+0.27)
Halozyme Announces Preclinical Study Results Of PEGPH20 Published In Molecular Cancer Therapeutics
PR Newswire - Tue Feb 17, 7:30AM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the manuscript "Tumor-Associated Hyaluronan Limits Efficacy of Monoclonal Antibody Therapy" has been published in Molecular Cancer Therapeutics (February 2015 14:523-532). The paper expands on previously reported data in a poster presentation at the American Society of Clinical Oncology 2015 Gastrointestinal Cancers Symposium in San Francisco, CA. The manuscript was written and funded by Halozyme Therapeutics, Inc.
HALO: 15.70 (+0.47)
Disney Is A Long-Term Buy - Cramer's Lightning Round (2/12/15)
SA Editor Mohit Manghnani - at Seeking Alpha - Fri Feb 13, 4:32AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday, February 12. Bullish Calls: Xerox (NYSE: XRX ): "The last quarter was not good and the stock should have gone down," said Cramer. He thinks...
FRPT: 17.36 (-0.23), COP: 64.25 (-0.53), DIS: 105.57 (-0.78), XRX: 13.37 (-0.06), PEP: 97.36 (-1.04), CELG: 119.57 (+1.10), DPS: 78.02 (-0.97), ZTS: 46.23 (-0.31), HALO: 15.70 (+0.47), ISIS: 70.16 (+1.50), TSRA: 39.62 (-2.11), MRK: 57.88 (-0.46), JUNO: 50.00 (+1.94), SPLK: 63.67 (-2.01), REGN: 413.04 (+0.53)
39.1% Return Seen to Date on SmarTrend Halozyme Therapeutics Call (HALO)
Comtex SmarTrend(R) - Tue Feb 10, 5:03PM CST
SmarTrend identified an Uptrend for Halozyme Therapeutics (NASDAQ:HALO) on January 5th, 2015 at $9.95. In approximately 1 month, Halozyme Therapeutics has returned 39.10% as of today's recent price of $13.84.
HALO: 15.70 (+0.47)
Biotech Stocks Technical Report - Halozyme Therapeutics, Agenus, Biogen Idec, ACADIA Pharma, and Peregrine Pharma
PR Newswire - Wed Jan 28, 7:40AM CST
Investor-Edge has initiated coverage on the following equities: Halozyme Therapeutics Inc. (NASDAQ: HALO), Agenus Inc. (NASDAQ: AGEN), Biogen Idec Inc. (NASDAQ: BIIB), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), and Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM). Free research report on Halozyme Therapeutics can be accessed at http://get.Investor-Edge.com/pdf/?c=Halozyme%...amp;s=HALO. On Tuesday, January 27, 2015, the NASDAQ Composite ended at 4,681.50, down 1.89%, the Dow Jones Industrial Average declined 1.65%, to finish the day at 17,387.21, and the S&P 500 closed at 2,029.55, down 1.34%. The losses were broad based as nine out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 818.80, down 0.75%, while the index has advanced 8.40% in the previous three months. Register for your complimentary reports at the links given below.
AGEN: 5.09 (+0.24), BIIB: 414.13 (+1.34), ACAD: 38.14 (unch), HALO: 15.70 (+0.47), PPHM: 1.47 (-0.01)
Halozyme Therapeutics Up 46.1% Since SmarTrend Uptrend Call (HALO)
Comtex SmarTrend(R) - Tue Jan 27, 9:36AM CST
SmarTrend identified an Uptrend for Halozyme Therapeutics (NASDAQ:HALO) on January 5th, 2015 at $9.95. In approximately 3 weeks, Halozyme Therapeutics has returned 46.13% as of today's recent price of $14.54.
HALO: 15.70 (+0.47)
Halozyme Appoints Jean-Pierre Bizzari, M.D. To Board Of Directors
PR Newswire - Wed Jan 21, 7:30AM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the appointment of Jean-Pierre Bizzari, M.D. to its Board of Directors. Dr. Bizzari brings extensive experience in oncology drug development.
HALO: 15.70 (+0.47)
Halozyme Therapeutics Has Returned 46.1% Since SmarTrend Recommendation (HALO)
Comtex SmarTrend(R) - Tue Jan 20, 9:06AM CST
SmarTrend identified an Uptrend for Halozyme Therapeutics (NASDAQ:HALO) on January 5th, 2015 at $9.95. In approximately 2 weeks, Halozyme Therapeutics has returned 46.07% as of today's recent price of $14.53.
HALO: 15.70 (+0.47)
Jim Cramer's Top Stock Picks: AAPL FLEX DIS CELG HALO
at The Street - Wed Jan 14, 5:00AM CST
Disney and Celgene have bankable CEOs while Halogen Therapeutics is involved in some promising treatments.
FLEX: 11.94 (+0.02), HALO: 15.70 (+0.47), DIS: 105.57 (-0.78), AAPL: 128.54 (-0.82), CELG: 119.57 (+1.10)
Halozyme Q4 Loss Narrower-than-Expected, Revenues Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 03, 9:33AM CST
Halozyme (HALO) reports narrower year over year loss in its fourth quarter; Gives 2015 view.
JNJ: 101.65 (-0.69), HALO: 15.70 (+0.47), CBM: 33.97 (+0.02), BAX: 69.25 (-0.17)
Halozyme Therapeutics ups revenues 143% in Q4
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 9:06AM CST
HALO: 15.70 (+0.47)
Halozyme Therapeutics' (HALO) CEO Helen Torley on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Mar 02, 7:00PM CST
HALO: 15.70 (+0.47)
Halozyme Therapeutics reports 4Q loss
Automated Insights - Mon Mar 02, 5:27PM CST
SAN DIEGO (AP) _ Halozyme Therapeutics Inc. (HALO) on Monday reported a loss of $5.3 million in its fourth quarter.
HALO: 15.70 (+0.47)
Halozyme Therapeutics beats by $0.03, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 3:20PM CST
HALO: 15.70 (+0.47)
Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results
PR Newswire - Mon Mar 02, 3:15PM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the fourth quarter and full year ended December 31, 2014. Financial highlights for the fourth quarter include revenues of $30.4 million and a net loss of $5.3 million, or $0.04 per share. This compares to revenues of $12.5 million and a net loss of $22.0 million, or $0.19 per share, for the fourth quarter of 2013. Financial highlights for the full year 2014 include revenues of $75.3 million and a net loss of $68.4 million, or $0.56 per share. This compares to revenues of $54.8 million and a net loss of $83.5 million, or $0.74 per share, in the prior year.
HALO: 15.70 (+0.47)
Notable earnings after Monday’s close
Seeking Alpha - at Seeking Alpha - Sun Mar 01, 4:35PM CST
MBI: 9.37 (+0.09), GWRE: 53.37 (-0.73), CODI: 16.58 (-0.13), MDR: 3.43 (+0.10), HTGC: 14.46 (-0.02), NBR: 12.84 (+0.23), NTRI: 18.73 (-0.61), XON: 48.11 (-0.04), STKL: 10.00 (+0.40), OPWR: 11.67 (+0.08), CZR: 10.36 (-0.22), PANW: 143.51 (-5.39), INN: 13.74 (+0.21), CMLS: 3.13 (-0.18), MTDR: 22.94 (+0.50), ARNA: 4.32 (+0.28), MCEP: 6.36 (+0.06), SLXP: 157.13 (+0.63), BALT: 1.63 (-0.04), MYL: 55.60 (+0.16), SN: 13.98 (+0.97), EPIQ: 17.55 (+0.13), CHUY: 23.22 (-0.76), DTSI: 33.34 (-0.38), PRAA: 48.29 (-1.45), HALO: 15.70 (+0.47), CIM: 3.16 (-0.02), CKEC: 30.74 (-0.13)
Next Week In Biotech: Pacira PDUFA, Geron And Dendreon Report
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 27, 8:00AM CST
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
BRLI: 36.51 (+1.31), CASM: 1.34 (+0.08), AMRN: 1.69 (+0.15), XON: 48.11 (-0.04), OSIR: 17.80 (+0.28), CPIX: 6.63 (+0.23), AMED: 29.43 (-0.53), CTIC: 2.46 (+0.04), INSY: 58.07 (+2.09), ECYT: 6.73 (+0.62), CMRX: 40.74 (+0.25), KYTH: 39.90 (+0.21), TRIB: 18.60 (+0.17), GALE: 1.95 (+0.10), ARNA: 4.32 (+0.28), XLRN: 41.01 (-0.16), ACRX: 9.11 (+0.18), ENDP: 85.65 (-0.23), DPLO: 30.78 (-0.19), SLXP: 157.13 (+0.63), PPHM: 1.47 (-0.01), MYL: 55.60 (+0.16), CBPO: 79.71 (+1.71), RGEN: 25.11 (+0.20), HALO: 15.70 (+0.47), ALIM: 5.21 (+0.03), ACHN: 11.63 (-0.51), GERN: 2.81 (-0.15), DARA: 0.85 (-0.09), SCMP: 14.82 (-0.15), ICPT: 266.49 (+19.13), CDXS: 3.90 (+0.12), PCRX: 95.39 (+1.45), PBYI: 206.96 (+0.95), FOLD: 8.41 (-0.07)
Next Week In Biotech: Arena And Vivus Report, Radiesse And Avedro Ad Comms
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 20, 8:00AM CST
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
LXRX: 1.05 (+0.07), AMRN: 1.69 (+0.15), HWAY: 22.28 (-0.01), HLS: 42.72 (-0.42), CYBX: 71.19 (+0.83), ESRX: 84.83 (+0.48), ECYT: 6.73 (+0.62), DXCM: 59.88 (+0.83), NSTG: 12.28 (+0.84), SRPT: 14.06 (+0.70), HZNP: 21.17 (+0.20), MDXG: 10.02 (-0.18), DEPO: 23.64 (+0.65), ANIK: 39.46 (unch), NKTR: 13.39 (+0.45), KERX: 13.26 (+0.22), ALIM: 5.21 (+0.03), EPZM: 24.01 (+0.64), AEGR: 28.02 (+0.56), MDRX: 12.32 (-0.03), ELGX: 16.04 (+0.11), NUVA: 45.01 (+0.75), HPTX: 29.73 (-0.05), GNMK: 12.58 (-0.20), MDVN: 121.01 (-0.37), HBIO: 5.61 (-0.17), ACAD: 38.14 (unch), ST: 56.03 (+0.25), RPTP: 10.30 (+0.69), FMI: 47.29 (-0.24), GMED: 24.03 (+0.07), JAZZ: 172.74 (-3.56), PTCT: 70.45 (+1.37), INFI: 16.17 (+0.21), ARNA: 4.32 (+0.28), EXEL: 3.05 (+0.05), NEO: 4.72 (+0.11), EXAS: 21.90 (+0.84), ALKS: 70.80 (-2.00), HTWR: 84.68 (-0.02), MNKD: 5.94 (-0.22), IPXL: 40.40 (+0.47), SQNM: 3.65 (-0.04), HALO: 15.70 (+0.47), ISIS: 70.16 (+1.50), CLVS: 77.40 (+1.85), BIO: 132.91 (-0.24), BIOS: 5.21 (-0.21), PCRX: 95.39 (+1.45)
Shares of HALO Up 53.1% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Feb 18, 9:09AM CST
SmarTrend identified an Uptrend for Halozyme Therapeutics (NASDAQ:HALO) on January 5th, 2015 at $9.95. In approximately 1 month, Halozyme Therapeutics has returned 53.07% as of today's recent price of $15.23.
HALO: 15.70 (+0.47)
Track What Biological Products Companies Are Up To: Special Research on Gilead, Halozyme, Heska, Idera, and Kite Pharma
PR Newswire - Tue Feb 17, 7:50AM CST
Editor Note: For more information about this release, please scroll to bottom.
HALO: 15.70 (+0.47), IDRA: 4.75 (+0.12), HSKA: 22.39 (+0.87), KITE: 63.19 (+1.72), GILD: 103.06 (+0.27)
Halozyme Announces Preclinical Study Results Of PEGPH20 Published In Molecular Cancer Therapeutics
PR Newswire - Tue Feb 17, 7:30AM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the manuscript "Tumor-Associated Hyaluronan Limits Efficacy of Monoclonal Antibody Therapy" has been published in Molecular Cancer Therapeutics (February 2015 14:523-532). The paper expands on previously reported data in a poster presentation at the American Society of Clinical Oncology 2015 Gastrointestinal Cancers Symposium in San Francisco, CA. The manuscript was written and funded by Halozyme Therapeutics, Inc.
HALO: 15.70 (+0.47)
Disney Is A Long-Term Buy - Cramer's Lightning Round (2/12/15)
SA Editor Mohit Manghnani - at Seeking Alpha - Fri Feb 13, 4:32AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday, February 12. Bullish Calls: Xerox (NYSE: XRX ): "The last quarter was not good and the stock should have gone down," said Cramer. He thinks...
FRPT: 17.36 (-0.23), COP: 64.25 (-0.53), DIS: 105.57 (-0.78), XRX: 13.37 (-0.06), PEP: 97.36 (-1.04), CELG: 119.57 (+1.10), DPS: 78.02 (-0.97), ZTS: 46.23 (-0.31), HALO: 15.70 (+0.47), ISIS: 70.16 (+1.50), TSRA: 39.62 (-2.11), MRK: 57.88 (-0.46), JUNO: 50.00 (+1.94), SPLK: 63.67 (-2.01), REGN: 413.04 (+0.53)
39.1% Return Seen to Date on SmarTrend Halozyme Therapeutics Call (HALO)
Comtex SmarTrend(R) - Tue Feb 10, 5:03PM CST
SmarTrend identified an Uptrend for Halozyme Therapeutics (NASDAQ:HALO) on January 5th, 2015 at $9.95. In approximately 1 month, Halozyme Therapeutics has returned 39.10% as of today's recent price of $13.84.
HALO: 15.70 (+0.47)
Biotech Stocks Technical Report - Halozyme Therapeutics, Agenus, Biogen Idec, ACADIA Pharma, and Peregrine Pharma
PR Newswire - Wed Jan 28, 7:40AM CST
Investor-Edge has initiated coverage on the following equities: Halozyme Therapeutics Inc. (NASDAQ: HALO), Agenus Inc. (NASDAQ: AGEN), Biogen Idec Inc. (NASDAQ: BIIB), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), and Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM). Free research report on Halozyme Therapeutics can be accessed at http://get.Investor-Edge.com/pdf/?c=Halozyme%...amp;s=HALO. On Tuesday, January 27, 2015, the NASDAQ Composite ended at 4,681.50, down 1.89%, the Dow Jones Industrial Average declined 1.65%, to finish the day at 17,387.21, and the S&P 500 closed at 2,029.55, down 1.34%. The losses were broad based as nine out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 818.80, down 0.75%, while the index has advanced 8.40% in the previous three months. Register for your complimentary reports at the links given below.
AGEN: 5.09 (+0.24), BIIB: 414.13 (+1.34), ACAD: 38.14 (unch), HALO: 15.70 (+0.47), PPHM: 1.47 (-0.01)
Halozyme Therapeutics Up 46.1% Since SmarTrend Uptrend Call (HALO)
Comtex SmarTrend(R) - Tue Jan 27, 9:36AM CST
SmarTrend identified an Uptrend for Halozyme Therapeutics (NASDAQ:HALO) on January 5th, 2015 at $9.95. In approximately 3 weeks, Halozyme Therapeutics has returned 46.13% as of today's recent price of $14.54.
HALO: 15.70 (+0.47)
Halozyme Appoints Jean-Pierre Bizzari, M.D. To Board Of Directors
PR Newswire - Wed Jan 21, 7:30AM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the appointment of Jean-Pierre Bizzari, M.D. to its Board of Directors. Dr. Bizzari brings extensive experience in oncology drug development.
HALO: 15.70 (+0.47)
Halozyme Therapeutics Has Returned 46.1% Since SmarTrend Recommendation (HALO)
Comtex SmarTrend(R) - Tue Jan 20, 9:06AM CST
SmarTrend identified an Uptrend for Halozyme Therapeutics (NASDAQ:HALO) on January 5th, 2015 at $9.95. In approximately 2 weeks, Halozyme Therapeutics has returned 46.07% as of today's recent price of $14.53.
HALO: 15.70 (+0.47)
Jim Cramer's Top Stock Picks: AAPL FLEX DIS CELG HALO
at The Street - Wed Jan 14, 5:00AM CST
Disney and Celgene have bankable CEOs while Halogen Therapeutics is involved in some promising treatments.
FLEX: 11.94 (+0.02), HALO: 15.70 (+0.47), DIS: 105.57 (-0.78), AAPL: 128.54 (-0.82), CELG: 119.57 (+1.10)
(0)
(0)Scroll down for more posts ▼